Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society
Open accessThe DOI matches its Crossref record; 134 of the 141 references it cites were found in a registry or an index; 90 of the 190 sources its claims cite were checked for support.
Abstract
OBJECTIVE: To review the evidence about the impact of hypoglycemia on patients with diabetes that has become available since the past reviews of this subject by the American Diabetes Association and The Endocrine Society and to provide guidance about how this new information should be incorporated into clinical practice. PARTICIPANTS: Five members of the American Diabetes Association and five members of The Endocrine Society with expertise in different aspects of hypoglycemia were invited by the Chair, who is a member of both, to participate in a planning conference call and a 2-day meeting that was also attended by staff from both organizations. Subsequent communications took place via e-mail and phone calls. The writing group consisted of those invitees who participated in the writing of the manuscript. The workgroup meeting was supported by educational grants to the American Diabetes Association from Lilly USA, LLC and Novo Nordisk and sponsorship to the American Diabetes Association from Sanofi. The sponsors had no input into the development of or content of the report. EVIDENCE: The writing group considered data from recent clinical trials and other studies to update the prior workgroup report. Unpublished data were not used. Expert opinion was used to develop some conclusions. CONSENSUS PROCESS: Consensus was achieved by group discussion during conference calls and face-to-face meetings, as well as by iterative revisions of the written document. The document was reviewed and approved by the American Diabetes Association's Professional Practice Committee in October 2012 and approved by the Executive Committee of the Board of Directors in November 2012 and was reviewed and approved by The Endocrine Society's Clinical Affairs Core Committee in October 2012 and by Council in November 2012. CONCLUSIONS: The workgroup reconfirmed the previous definitions of hypoglycemia in diabetes, reviewed the implications of hypoglycemia on both short- and long-term outcomes, considered the implications of hypoglycemia on treatment outcomes, presented strategies to prevent hypoglycemia, and identified knowledge gaps that should be addressed by future research. In addition, tools for patients to report hypoglycemia at each visit and for clinicians to document counseling are provided.
Overview
CoChat Summary
TL;DR
This ADA/Endocrine Society workgroup report updates definitions, risks, and prevention strategies for hypoglycemia in diabetes, with a strong emphasis on avoiding severe episodes and hypoglycemia unawareness. It argues for individualized glycemic targets, better monitoring and education, and further research on outcomes, measurement, and new therapies.
Key findings
- The workgroup defines iatrogenic hypoglycemia as all episodes of abnormally low plasma glucose that expose the person to potential harm, and recommends an alert value of ≤70 mg/dL (≤3.9 mmol/L) for patients at risk; it also classifies episodes as severe, documented symptomatic, asymptomatic, probable symptomatic, or pseudo-hypoglycemia.
- Severe hypoglycemia rates reported in the paper ranged from 115 to 320 per 100 patient-years in type 1 diabetes and 35 to 70 per 100 patient-years in type 2 diabetes; because type 2 diabetes is more common, most hypoglycemia episodes occur in people with type 2 diabetes.
- In ACCORD, intensive glycemic control produced threefold higher hypoglycemia and a 20% increase in mortality; post hoc analyses in ACCORD found severe hypoglycemia had a hazard ratio of 1.41 (95% CI 1.03–1.93) for death.
- In hospitalized patients, one retrospective study found 10.5% of 31,970 general-ward admissions had at least one hypoglycemic episode (≤70 mg/dL), and severe hypoglycemia (≤50 mg/dL) was associated with increased length of stay and greater odds of inpatient death and death within 1 year of discharge.
Methods
- This is a workgroup report/consensus document, not an experimental study; five ADA and five Endocrine Society experts were invited, held a planning call and a 2-day meeting, and developed the manuscript through discussion and iterative revisions.
- The group reviewed recent clinical trials and other studies published since the prior reports; unpublished data were not used, and some conclusions relied on expert opinion.
- Consensus was reached by group discussion and was reviewed/approved by both organizations’ committees in October and November 2012.
Limitations
- The paper states that unpublished data were not used, and that expert opinion was used to develop some conclusions.
- The text makes evident that some evidence is observational, post hoc, or limited by small studies, so causal inference is uncertain in several areas (e.g., mortality, cognition); this is an inference from the paper’s cited evidence, not a limitation explicitly stated in one place.
- The paper explicitly notes gaps in knowledge on hypoglycemia outcomes, mechanisms, and prevention, indicating that several recommendations are based on incomplete evidence.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
59 Valid · 5 Not valid · 33 Not checked · 7 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“There is convincing evidence that formal training programs that teach patients to replace insulin “physiologically” by giving background and mealtime/correction doses of insulin can reduce the risk of severe hypoglycemia.”
§ Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society > What strategies are known to prevent hypoglycemia, and what are the clinical recommendations for those at risk for hypoglycemia? > Patient education
What the sources say
- Supportedcites [100] Mühlhauser, 2002, Patient education—evaluation of a complex intervention, Diabetologia source
The Modelling section describes a structured programme teaching patients to adjust insulin doses, using NPH insulin twice daily and regular insulin before meals. The Long-term implementation section reports decreased rates of severe hypoglycaemia in patients with Type I diabetes and says several prospective studies observed that reduction. The paper supports that such programmes can reduce the risk, although not every evaluation found a reduction. (LLM, conf=0.90)
- Partly supportedcites [101] Bott, 1997, Intensified insulin therapy and the risk of severe hypoglycaemia, Diabetologia sourceExperimental — accuracy not yet measured
The Subjects and methods passage describes structured training in background and mealtime insulin dosing, with patients adjusting doses for glucose and carbohydrate intake. The Results and Discussion report fewer severe hypoglycaemic episodes after the programme, but describe the reduction as an association; they do not establish that training itself caused it. The claim’s description of this as convincing evidence that the programmes can reduce risk is therefore stronger than the paper’s finding. (LLM, conf=0.84)
- Supportedcites [102] Sämann, 2005, Glycaemic control and severe hypoglycaemia following training in flexible, intensive insulin therapy to enable dietary freedom in people with type 1 diabetes: a prospective implementation study, Diabetologia source
The Subjects and methods section describes a structured course teaching background insulin injections and meal-by-meal dose adjustments based on blood glucose and carbohydrate intake. The Abstract reports that severe hypoglycaemia fell from 0.37 to 0.14 events per patient per year after training among people with type 1 diabetes. (LLM, conf=0.92)
- Disputedcites [103] DAFNE Study Group, 2002, Training in flexible, intensive insulin management to enable dietary freedom in people with type 1 diabetes: dose adjustment for normal eating (DAFNE) randomised controlled trial, BMJ sourceExperimental — accuracy not yet measured
The skills course section describes training patients to adjust insulin to their meals. But the paper reports that severe hypoglycaemia remained unchanged; the Discussion says there was no significant increase, not a reduction in risk. The claimed risk reduction is therefore contrary to the reported finding. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
- Not checked — no full text of the sourcecites [104] McIntyre, 2010, Dose adjustment for normal eating (DAFNE)—an audit of outcomes in Australia, Med J Aust source
- Partly supportedcites [105] Hopkins, 2012, Improved biomedical and psychological outcomes 1 year after structured education in flexible insulin therapy for people with type 1 diabetes: the U.K. DAFNE experience, Diabetes Care sourceExperimental — accuracy not yet measured
The Results and Conclusions (pages not provided) report fewer severe hypoglycemia episodes after DAFNE, a structured education program for adults with type 1 diabetes. The paper describes adjusting insulin to carbohydrate intake, but does not specify the claimed background and mealtime/correction-dose teaching. Its evidence is also a retrospective audit based on self-reported hypoglycemia, which qualifies the claim of ‘convincing evidence.’ (LLM, conf=0.82)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“glycemic thresholds for symptoms of hypoglycemia (among other responses) shift to lower plasma glucose concentrations after recent antecedent hypoglycemia (9–12)”
§ Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society > How should hypoglycemia in diabetes be defined and reported?
What the sources say
- Not checked — no full text of the sourcecites [9] Amiel, 1988, Effect of intensive insulin therapy on glycemic thresholds for counterregulatory hormone release, Diabetes source
- Supportedcites [10] Dagogo-Jack, 1993, Hypoglycemia-associated autonomic failure in insulin-dependent diabetes mellitus. Recent antecedent hypoglycemia reduces autonomic responses to, symptoms of, and defense against subsequent hypoglycemia, J Clin Invest source
The Discussion states that after an episode of hypoglycemia, the authors found elevated glycemic thresholds for neurogenic and neuroglycopenic symptoms, including in patients with IDDM in the present study. Its terminology indicates that an elevated threshold means symptoms occur at a lower plasma glucose concentration. The Results also report reduced symptom responses after antecedent hypoglycemia. (LLM, conf=0.90)
- Not checked — no full text of the sourcecites [11] Davis, 1997, Effects of differing antecedent hypoglycemia on subsequent counterregulation in normal humans, Diabetes source
- Not checked — no full text of the sourcecites [12] Heller, 1991, Reduced neuroendocrine and symptomatic responses to subsequent hypoglycemia after 1 episode of hypoglycemia in nondiabetic humans, Diabetes source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In critical care units, where the accuracy of POC meters is particularly crucial, their performance may be compromised by medications (vasopressors, acetaminophen), treatments (oxygen), and clinical states (hypotension, anemia) (17).”
§ Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society > How should hypoglycemia in diabetes be defined and reported? > The challenge of measuring glucose accurately
What the sources say
- Partly supportedcites [17] Klonoff, 2011, Continuous glucose monitoring: an Endocrine Society Clinical Practice Guideline, J Clin Endocrinol Metab sourceExperimental — accuracy not yet measured
Section 1.1 Evidence says supplemental oxygen can cause falsely low readings with glucose-oxidase meters and identifies acetaminophen, pressor use, and hypotension as potential concerns for POC testing in critically ill patients. It also reports an accuracy discrepancy among patients with hypotension or pressor treatment. The cited passages do not address anemia as a cause of compromised meter performance. (LLM, conf=0.88)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“A single threshold value for plasma glucose concentration that defines hypoglycemia in diabetes cannot be assigned because glycemic thresholds for symptoms of hypoglycemia (among other responses) shift to lower plasma glucose concentrations after recent antecedent hypoglycemia (9–12) and to higher plasma glucose concentrations in patients with poorly controlled diabetes and infrequent hypoglycemia”
§ Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society > How should hypoglycemia in diabetes be defined and reported?
What the sources say
- Not checked — no full text of the sourcecites [9] Amiel, 1988, Effect of intensive insulin therapy on glycemic thresholds for counterregulatory hormone release, Diabetes source
- Supportedcites [10] Dagogo-Jack, 1993, Hypoglycemia-associated autonomic failure in insulin-dependent diabetes mellitus. Recent antecedent hypoglycemia reduces autonomic responses to, symptoms of, and defense against subsequent hypoglycemia, J Clin Invest source
The Discussion (p. 823) reports that antecedent hypoglycemia changes the glycemic threshold for symptoms in patients with insulin-dependent diabetes. The Discussion also reports symptoms at higher plasma glucose concentrations in patients with poorly or moderately controlled diabetes. Together, these findings support the claim that no single symptom-based plasma glucose threshold applies across these circumstances. (LLM, conf=0.91)
- Not checked — no full text of the sourcecites [11] Davis, 1997, Effects of differing antecedent hypoglycemia on subsequent counterregulation in normal humans, Diabetes source
- Not checked — no full text of the sourcecites [12] Heller, 1991, Reduced neuroendocrine and symptomatic responses to subsequent hypoglycemia after 1 episode of hypoglycemia in nondiabetic humans, Diabetes source
- Not checked — no full text of the sourcecites [13] Boyle, 1988, Plasma glucose concentrations at the onset of hypoglycemic symptoms in patients with poorly controlled diabetes and in nondiabetics, N Engl J Med source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Hypoglycemia puts patients at risk for injury and death.”
- Also stated in: § What are the implications of hypoglycemia on both short- and long-term outcomes in people with diabetes? · plain
“There is no doubt that hypoglycemia can be fatal (26).”
§ Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society > How should hypoglycemia in diabetes be defined and reported?
What the sources say
- Supportedcites [26] Cryer, 2011, Death during intensive glycemic therapy of diabetes: mechanisms and implications, Am J Med source
In the main text (page unavailable), Cryer states that iatrogenic hypoglycemia causes recurrent morbidity in people with diabetes and is sometimes fatal. This supports the broad claim that hypoglycemia puts these patients at risk of harm and death. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § What are the implications of hypoglycemia on both short- and long-term outcomes in people with diabetes? · plain
76 more claims · 43 with their cited sources checked
Create a free account to see all 104 claims and to verify the 4 references still open.
- It may state two separate claims as one. 21
- Probably not a substantial claim. 2
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Postprandial hyperglycemia and resultant compensatory hyperinsulinemia from high dietary glycemic load can lower plasma glucose to concentrations that compromise brain glucose, w70 mg/dL (3.8 mmol/L) (36), triggering the secretion of autonomic counterregulatory hormones such as adrenaline, cortisol, glucagon, and growth hormone (37).”
From High glycemic index diet as a risk factor for depression: analyses from the Women’s Health Initiative (2015) · cites this paper as [36]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Risks for hypoglycemia, particularly level 3 hypoglycemia, include longer duration of diabetes, older age, history of recent level 3 hypoglycemia, alcohol ingestion, exercise, lower education levels, lower household incomes (41), chronic kidney disease, and IAH (103-105).”
From The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2021) · cites this paper as [103]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Recurrent hypoglycaemia results in an increased likelihood of hypoglycaemia unawareness and subsequent severe hypoglycaemic events, since recurrent hypoglycaemia reduces the glucose concentration that triggers the counter-regulatory responses to return to euglycaemia.106”
From Type 1 diabetes (2018) · cites this paper as [106]
The cited source says what the claim attributes to it.
In the citing paper
“Hypoglycemia is a frequent and dangerous complication of diabetes (1), causing changes in physiological parameters (2,3).”
From Noninvasive Hypoglycemia Detection in People With Diabetes Using Smartwatch Data (2023) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“Individualized glucose targets, patient education, nutrition intervention (e.g., bedtime snack to prevent overnight hypoglycemia when specifically needed to treat low blood glucose), physical activity management, medication adjustment, glucose monitoring, and routine clinical surveillance may improve patient outcomes (94).”
From 6. Glycemic Targets: Standards of Care in Diabetes—2023 (2023) · cites this paper as [94]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Self-check results appear here once an independent check has confirmed them.
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
A note, not an issue: for example, a cited work that was retracted only after this paper was published, which its authors could not have known.
In the paper
“Deakin T McShane CE Cade JE Williams RD Group based training for self-management strategies in people with type 2 diabetes mellitus. Cochrane Database Syst Rev 2005; 2: CD003417 15846663”
Cited work 10.1002/14651858.cd003417.pub2 · retracted 2015-06-30 · notice 10.1002/14651858.cd003417.pub3 · this paper published 2013-04-13
Citations
Cites
1 retracted
Group based training for self-management strategies in people with type 2 diabetes mellitus
Deakin, T. A., McShane, C. E., Cade, J. E., & Williams, R. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003417.pub2 · Cited by 862
RetractedIntensive insulin therapy in critically ill patients.
Van den Berghe, G., Wouters, P., Weekers, F., Verwaest, C., Bruyninckx, F., Schetz, M., Vlasselaers, D., Ferdinande, P., Lauwers, P., & Bouillon, R. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011300 · Cited by 9,977
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Hyperglycemia and adverse pregnancy outcomes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707943 · Cited by 5,563
Intensive versus Conventional Glucose Control in Critically Ill Patients
(2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810625 · Cited by 5,119
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762 · cited 1×
“In VADT, a recent severe hypoglycemic event was the strongest independent predictor of death at 90 days (3).”
BackgroundInzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919 · cited 2×
“event of troublesome hypoglycemia (96).”
BackgroundIntensive insulin therapy in the medical ICU
Van den Berghe, G., Wilmer, A., Hermans, G., Meersseman, W., Wouters, P. J., Milants, I., Van Wijngaerden, E., Bobbaers, H., & Bouillon, R. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052521 · Cited by 3,639
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetes Care · doi:10.2337/dc12-0413 · Cited by 3,207
Research works printed but not linked: 2
- Reno, 2011, Deaths due to severe hypoglycemia are exacerbated by diabetes and ameliorated by hypoglycemic pre-conditioning (Abstract), Diabetes, 60, A81
- Aubert, 1995, Diabetes-Related Hospitalization and Hospital Utilization
Cited by
Items 101–200 of 1,392
DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality
on behalf of the DEVOTE Study Group, Pieber, T. R., Marso, S. P., McGuire, D. K., Zinman, B., Poulter, N. R., Emerson, S. S., Pratley, R. E., Woo, V., Heller, S., et al. (2018) · Diabetologia · doi:10.1007/s00125-017-4422-0 · Cited by 148
“Plasma glucose levels may not be available during an event, but neurological recovery after the return of plasma glucose to a normal level is considered sufficient evidence that the event was induced by a low plasma glucose level [19].”
BackgroundSelf-citationManagement of hypoglycemia in older adults with type 2 diabetes
Freeman, J. (2019) · Postgraduate Medicine · doi:10.1080/00325481.2019.1578590 · Cited by 144
“appears to depend on how frequently they experience hypoglycemia [12].”
BackgroundInfluentialDomínguez Avila, J., Rodrigo García, J., González Aguilar, G., & De la Rosa, L. (2017) · Molecules · doi:10.3390/molecules22060903 · Cited by 143
“They are considered safe in most cases, but one of their main and most serious side effects is hypoglycemia [26].”
BackgroundPathak, R. D., Schroeder, E. B., Seaquist, E. R., Zeng, C., Lafata, J. E., Thomas, A., Desai, J., Waitzfelder, B., Nichols, G. A., Lawrence, J. M., et al. (2016) · Diabetes Care · doi:10.2337/dc15-0858 · Cited by 140
“tients with diabetes was recently addressed by a working group of the American Diabetes Association and The Endocrine Society (39).”
BackgroundSelf-citationNeuronal damage and cognitive impairment associated with hypoglycemia: An integrated view
Languren, G., Montiel, T., Julio-Amilpas, A., & Massieu, L. (2013) · Neurochemistry International · doi:10.1016/j.neuint.2013.06.018 · Cited by 156
“These include patient’s education, dietary intervention, exercise management, medication adjustment, glucose monitoring and clinical surveillance (Seaquist et al., 2013).”
Rizzo, M., Rizvi, A. A., Patti, A. M., Nikolic, D., Giglio, R. V., Castellino, G., Li Volti, G., Caprio, M., Montalto, G., Provenzano, V., et al. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0480-8 · Cited by 135
“Fifteen subjects reported symptomatic hypoglycemia; however, no severe hypoglycemic episodes (based on the joint American Diabetes Association and the Endocrine Society definition) were recorded [11].”
BackgroundThethi, T. K., Pratley, R., & Meier, J. J. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14054 · Cited by 134
Elliott, L., Fidler, C., Ditchfield, A., & Stissing, T. (2016) · Diabetes Therapy · doi:10.1007/s13300-016-0157-z · Cited by 135
“Severe hypoglycemia by its very nature carries the risk of injury and can even be life-threatening to a patient with diabetes if not managed promptly [60].”
BackgroundA Pharmacological and Clinical Overview of Oral Semaglutide for the Treatment of Type 2 Diabetes
Andersen, A., Knop, F. K., & Vilsbøll, T. (2021) · Drugs · doi:10.1007/s40265-021-01499-w · Cited by 133
Danne, T., Biester, T., Kapitzke, K., Jacobsen, S. H., Jacobsen, L. V., Petri, K. C. C., Hale, P. M., & Kordonouri, O. (2017) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2016.10.076 · Cited by 132
Safety and tolerability of once‐weekly GLP‐1 receptor agonists in type 2 diabetes
Trujillo, J. (2020) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13225 · Cited by 130
Cariou, B., Fontaine, P., Eschwege, E., Lièvre, M., Gouet, D., Huet, D., Madani, S., Lavigne, S., & Charbonnel, B. (2015) · Diabetes & Metabolism · doi:10.1016/j.diabet.2014.10.007 · Cited by 129
Martyn-Nemeth, P., Quinn, L., Penckofer, S., Park, C., Hofer, V., & Burke, L. (2017) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.12.015 · Cited by 128
6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026.
American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care · doi:10.2337/dc26-s006 · Cited by 172
Bailey, T. S., Grunberger, G., Bode, B. W., Handelsman, Y., Hirsch, I. B., Jovanovič, L., Roberts, V. L., Rodbard, D., Tamborlane, W. V., & Walsh, J. S. A. (2016) · Endocrine Practice · doi:10.4158/ep151124.cs · Cited by 150
Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects with Renal Impairment
Granhall, C., Søndergaard, F. L., Thomsen, M., & Anderson, T. W. (2018) · Clinical Pharmacokinetics · doi:10.1007/s40262-018-0649-2 · Cited by 125
“Documented symptomatic hypoglycaemia (according to ADA classification) [22] was also low (three subjects [five events] in the moderate renal impairment group and two subjects [two events] in the severe renal impairment group).”
BackgroundMethodInfluentialGangwisch, J. E., Hale, L., St-Onge, M.-P., Choi, L., LeBlanc, E. S., Malaspina, D., Opler, M. G., Shadyab, A. H., Shikany, J. M., Snetselaar, L., et al. (2020) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/nqz275 · Cited by 123
Improving pregnancy outcomes in women with diabetes mellitus: modern management
Ringholm, L., Damm, P., & Mathiesen, E. R. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0197-3 · Cited by 142
Hypoglycemia in Patients with Diabetes and Renal Disease
Alsahli, M., & Gerich, J. (2015) · Journal of Clinical Medicine · doi:10.3390/jcm4050948 · Cited by 123
“The American Diabetes Association and Endocrine Society workgroup on hypoglycemia defined iatrogenic hypoglycemia in patients with diabetes as all episodes of an abnormally low plasma glucose concentration that expose the patient to potential harm [15].”
BackgroundInfluentialIncidence of Hypoglycemia After Gastric Bypass vs Sleeve Gastrectomy: A Randomized Trial
Capristo, E., Panunzi, S., De Gaetano, A., Spuntarelli, V., Bellantone, R., Giustacchini, P., Birkenfeld, A. L., Amiel, S., Bornstein, S. R., Raffaelli, M., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-01695 · Cited by 122
Foos, V., Varol, N., Curtis, B. H., Boye, K. S., Grant, D., Palmer, J. L., & McEwan, P. (2015) · Journal of Medical Economics · doi:10.3111/13696998.2015.1006730 · Cited by 120
Bowering, K., Case, C., Harvey, J., Reeves, M., Sampson, M., Strzinek, R., Bretler, D.-M., Bang, R. B., & Bode, B. W. (2017) · Diabetes Care · doi:10.2337/dc16-1770 · Cited by 119
“Severe hypoglycemia was defined according to the ADA classification (17).”
BackgroundMethodHeise, T., Nørskov, M., Nosek, L., Kaplan, K., Famulla, S., & Haahr, H. L. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12938 · Cited by 118
Maffeis, C., Birkebæk, N., Konstantinova, M. M., Schwandt, A., Vazeou, A., Casteels, K., Jali, S. M., Limbert, C., Pundziūtė-Lyckå, A., Tóth‐Heyn, P., et al. (2018) · Pediatric Diabetes · doi:10.1111/pedi.12730 · Cited by 134
“unhealthy eating habits, may contribute to favor a positive energy balance.(30,31) Other factors favoring body fat accumulation are specific to”
BackgroundMcAuley, S. A., Trawley, S., Vogrin, S., Ward, G. M., Fourlanos, S., Grills, C. A., Lee, M. H., Alipoor, A. M., O’Neal, D. N., O’Regan, N. A., et al. (2022) · Diabetes Care · doi:10.2337/dc21-1667 · Cited by 117
Lee, A. K., Rawlings, A. M., Lee, C. J., Gross, A. L., Huang, E. S., Sharrett, A. R., Coresh, J., & Selvin, E. (2018) · Diabetologia · doi:10.1007/s00125-018-4668-1 · Cited by 115
Pathway to Artificial Pancreas Systems Revisited: Moving Downstream
Kowalski, A. (2015) · Diabetes Care · doi:10.2337/dc15-0364 · Cited by 113
Phase 3 trial of human islet-after-kidney transplantation in type 1 diabetes
Markmann, J. F., Rickels, M. R., Eggerman, T. L., Bridges, N. D., Lafontant, D. E., Qidwai, J., Foster, E., Clarke, W. R., Kamoun, M., Alejandro, R., et al. (2021) · American Journal of Transplantation · doi:10.1111/ajt.16174 · Cited by 111
Ji, L., Dong, X., Li, Y., Li, Y., Lim, S., Liu, M., Ning, Z., Rasmussen, S., Skjøth, T. V., Yuan, G., et al. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14232 · Cited by 113
Predictors of time in target glucose range in real‐world users of the MiniMed 780G system
Castañeda, J., Mathieu, C., Aanstoot, H., Arrieta, A., Da Silva, J., Shin, J., & Cohen, O. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14807 · Cited by 106
“The recommended target of 100 mg/dl is also proposed for the majority of users, while a target of 110 mg/dl is recommended in the following situations: (a) age <15 years;(17) (b) when concerned about exacerbation of retinopathy when glucose levels are reduced rapidly (may use target of 120 mg/dl)(26); and (c) presence…”
BackgroundFrandsen, C. S., Dejgaard, T. F., Holst, J. J., Andersen, H. U., Thorsteinsson, B., & Madsbad, S. (2015) · Diabetes Care · doi:10.2337/dc15-1037 · Cited by 103
“requiring assistance of another person to actively administer carbohydrates, glucagon, or take other corrective actions with or without measurement of blood glucose levels (33).”
BackgroundJohnson, M. L., Martens, T. W., Criego, A. B., Carlson, A. L., Simonson, G. D., & Bergenstal, R. M. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0034 · Cited by 104
Basal insulin analogues in the management of diabetes mellitus: what progress have we made?
Owens, D. R., Matfin, G., & Monnier, L. (2014) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2469 · Cited by 108
“Definition of hypoglycaemia in the phase III degludec trials [90] and American Diabetes Association 2005 and 2013 consensus [86,87]”
BackgroundHypoglycemia in patient with type 2 diabetes treated with insulin: it can happen
Heller, S. R., Peyrot, M., Oates, S. K., & Taylor, A. D. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001194 · Cited by 101
Self-citationMorales, J., & Schneider, D. (2014) · The American Journal of Medicine · doi:10.1016/j.amjmed.2014.07.004 · Cited by 130
Dungan, K. M., Weitgasser, R., Perez Manghi, F., Pintilei, E., Fahrbach, J. L., Jiang, H. H., Shell, J., & Robertson, K. E. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12634 · Cited by 99
“Severe hypoglycaemia was defined as an episode requiring the assistance of another person to actively administer carbohydrate, glucagon or other resuscitative actions [13].”
BackgroundGallwitz, B., Dagogo‐Jack, S., Thieu, V., Garcia‐Perez, L., Pavo, I., Yu, M., Robertson, K. E., Zhang, N., & Giorgino, F. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13086 · Cited by 98
Self-citationRickels, M. R., Stock, P. G., de Koning, E. J. P., Piemonti, L., Pratschke, J., Alejandro, R., Bellin, M. D., Berney, T., Choudhary, P., Johnson, P., et al. (2018) · Transplantation · doi:10.1097/tp.0000000000002158 · Cited by 104
Abraham, M. B., Karges, B., Dovč, K., Naranjo, D. M., Arbeláez, A. M., Mbogo, J., Javelikar, G., Jones, T. W., & Mahmud, F. H. (2022) · Pediatric Diabetes · doi:10.1111/pedi.13443 · Cited by 141
“This aligns with the definition of severe hypoglycemia in adults in accordance with the American Diabetes Association (ADA) guidelines.(17) This will also enable complete recording of events.”
ResultHYPOS-1 Study Group of AMD, Giorda, C. B., Ozzello, A., Gentile, S., Aglialoro, A., Chiambretti, A., Baccetti, F., Gentile, F. M., Lucisano, G., Nicolucci, A., et al. (2015) · Acta Diabetologica · doi:10.1007/s00592-015-0713-4 · Cited by 97
Conlin, P. R., Colburn, J., Aron, D., Pries, R. M., Tschanz, M. P., & Pogach, L. (2017) · Annals of Internal Medicine · doi:10.7326/m17-1362 · Cited by 97
Rickels, M. R., Stock, P. G., de Koning, E. J. P., Piemonti, L., Pratschke, J., Alejandro, R., Bellin, M. D., Berney, T., Choudhary, P., Johnson, P. R., et al. (2018) · Transplant International · doi:10.1111/tri.13138 · Cited by 97
Mathieu, C., Bode, B. W., Franek, E., Philis‐Tsimikas, A., Rose, L., Graungaard, T., Birk Østerskov, A., & Russell‐Jones, D. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13205 · Cited by 95
Leiter, L. A., Carr, M. C., Stewart, M., Jones-Leone, A., Scott, R., Yang, F., & Handelsman, Y. (2014) · Diabetes Care · doi:10.2337/dc13-2855 · Cited by 95
Pharmacokinetics, Safety, and Tolerability of Oral Semaglutide in Subjects With Hepatic Impairment
Bækdal, T. A., Thomsen, M., Kupčová, V., Hansen, C. W., & Anderson, T. W. (2018) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1131 · Cited by 95
Musso, G., Gambino, R., Cassader, M., & Paschetta, E. (2019) · BMJ · doi:10.1136/bmj.l1328 · Cited by 94
Ratzki-Leewing, A., Harris, S. B., Mequanint, S., Reichert, S. M., Belle Brown, J., Black, J. E., & Ryan, B. L. (2018) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2017-000503 · Cited by 90
“Notwithstanding, the outcome measures, based on participant self-report, employed in the current study encompassed several pragmatic classifications of hypoglycemia considered important in the clinical management of diabetes: documented symptomatic hypoglycemia, probable symptomatic hypoglycemia, as well as pseudo-hyp…”
BackgroundCzupryniak, L., Barkai, L., Bolgarska, S., Bronisz, A., Broz, J., Cypryk, K., Honka, M., Janez, A., Krnic, M., Lalic, N., et al. (2014) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2013.0302 · Cited by 93
Engineering Glucose Responsiveness Into Insulin
Kaarsholm, N. C., Lin, S., Yan, L., Kelly, T., van Heek, M., Mu, J., Wu, M., Dai, G., Cui, Y., Zhu, Y., et al. (2018) · Diabetes · doi:10.2337/db17-0577 · Cited by 91
“Introduction Nearly a century has passed since the discovery of insulin yet the remarkable success of insulin therapy has been tempered by the risk of iatrogenic hypoglycemia, which stands as a major barrier to achievement of tight glycemic control [1-4].”
BackgroundAssociation between hypoglycemia and dementia in patients with type 2 diabetes
Sheen, Y., & Sheu, W. H. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2016.04.004 · Cited by 105
“Plasma values for classification of hypoglycemia in diabetes [20,21].”
Mastrandrea, L. D., Witten, L., Carlsson Petri, K. C., Hale, P. M., Hedman, H. K., & Riesenberg, R. A. (2019) · Pediatric Obesity · doi:10.1111/ijpo.12495 · Cited by 94
“9 mmol L).(27) A total of six hypoglycaemic episodes were reported; there were no severe, documented symptomatic, probable symptomatic, or relative hypoglycaemic episodes.”
BackgroundThalange, N., Deeb, L., Iotova, V., Kawamura, T., Klingensmith, G., Philotheou, A., Silverstein, J., Tumini, S., Ocampo Francisco, A., Kinduryte, O., et al. (2015) · Pediatric Diabetes · doi:10.1111/pedi.12263 · Cited by 91
“This property is especially beneficial for young children, where nocturnal hypoglycemia is of particular concern (36, 37).”
BackgroundZhang, B., Cheng, Z., Chen, J., Zhang, X., Liu, D., Jiang, H., Ma, G., Wang, X., Gan, S., Sun, J., et al. (2024) · Diabetes Care · doi:10.2337/dc23-1287 · Cited by 91
14. Diabetes Care in the Hospital
American Diabetes Association (2016) · Diabetes Care · doi:10.2337/dc17-s017 · Cited by 110
Once-Weekly Exenatide in Youth With Type 2 Diabetes
Tamborlane, W. V., Bishai, R., Geller, D., Shehadeh, N., Al-Abdulrazzaq, D., Vazquez, E. M., Karoly, E., Troja, T., Doehring, O., Carter, D., et al. (2022) · Diabetes Care · doi:10.2337/dc21-2275 · Cited by 91
“The definition of “major” hypoglycemia that was applied in the study is distinct from the current ADA definition (16,17) of “severe” hypoglycemia that was programmatically derived after the study had been completed.”
BackgroundInfluentialDavenport, M. H., Sobierajski, F., Mottola, M. F., Skow, R. J., Meah, V. L., Poitras, V. J., Gray, C. E., Jaramillo Garcia, A., Barrowman, N., Riske, L., et al. (2018) · British Journal of Sports Medicine · doi:10.1136/bjsports-2018-099829 · Cited by 90
Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes Mellitus
Kirkman, M. S., Mahmud, H., & Korytkowski, M. T. (2018) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2017.10.002 · Cited by 96
Understanding hypoglycemia in hospitalized patients
Hulkower, R. D., Pollack, R. M., & Zonszein, J. (2014) · Diabetes Management · doi:10.2217/dmt.13.73 · Cited by 89
Recognition and management of hyperinsulinemic hypoglycemia after bariatric surgery
Malik, S., Mitchell, J. E., Steffen, K., Engel, S., Wiisanen, R., Garcia, L., & Malik, S. A. (2016) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2015.07.003 · Cited by 86
“Qintar M, Sibai F, Taha M. Hypoglycemia due to an adult-onset nesidioblastosis, a diagnostic and management dilemma.”
InfluentialAlramadan, M. J., Magliano, D. J., Almigbal, T. H., Batais, M. A., Afroz, A., Alramadhan, H. J., Mahfoud, W. F., Alragas, A. M., & Billah, B. (2018) · BMC Endocrine Disorders · doi:10.1186/s12902-018-0292-9 · Cited by 106
Tamborlane, W. V., Laffel, L. M., Shehadeh, N., ISGANAITIS, E. M., Name, M. A. V., Ratnayake, J., Karlsson, C., & Norjavaara, E. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00052-3 · Cited by 90
13. Diabetes Care in the Hospital
American Diabetes Association (2015) · Diabetes Care · doi:10.2337/dc16-s016 · Cited by 104
Little, S. A., Speight, J., Leelarathna, L., Walkinshaw, E., Tan, H. K., Bowes, A., Lubina-Solomon, A., Chadwick, T. J., Stocken, D. D., Brennand, C., et al. (2018) · Diabetes Care · doi:10.2337/dc17-2682 · Cited by 86
Self-citationDiabetes Self-Care and the Older Adult
Weinger, K., Beverly, E. A., & Smaldone, A. M. (2014) · Western Journal of Nursing Research · doi:10.1177/0193945914521696 · Cited by 115
The risk factors of inpatient hypoglycemia: A systematic review
Pratiwi, C., Mokoagow, M. I., Kshanti, I. A., & Soewondo, P. (2020) · Heliyon · doi:10.1016/j.heliyon.2020.e03913 · Cited by 90
Lin, Y. K., Fisher, S. J., & Pop‐Busui, R. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13290 · Cited by 82
Movahed, A., Raj, P., Nabipour, I., Mahmoodi, M., Ostovar, A., Kalantarhormozi, M., & Netticadan, T. (2020) · Nutrients · doi:10.3390/nu12010161 · Cited by 87
“Treatment-induced hypoglycemia is known to negatively impact the patient’s adherence to insulin treatment [4,5].”
BackgroundAmerican Diabetes Association (2016) · Diabetes Care · doi:10.2337/dc16-s014 · Cited by 82
Lingvay, I., Desouza, C. V., Lalic, K. S., Rose, L., Hansen, T., Zacho, J., & Pieber, T. R. (2018) · Diabetes Care · doi:10.2337/dc17-2381 · Cited by 81
Lin, Y. K., Hung, M., Sharma, A., Chan, O., Varner, M. W., Staskus, G., & Fisher, S. J. (2019) · Endocrine Practice · doi:10.4158/ep-2018-0527 · Cited by 81
“A severe hypoglycemic event was defined as a hypoglycemic episode requiring assistance for treatment administration (23).”
BackgroundKlonoff, D. C., Evans, M. L., Lane, W. S., Kempe, H., Renard, É., DeVries, J. H., Graungaard, T., Hyseni, A., Gondolf, T., & Battelino, T. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13610 · Cited by 85
Clinical practice guidelines for congenital hyperinsulinism
Yorifuji, T., Horikawa, R., Hasegawa, T., Adachi, M., Soneda, S., Minagawa, M., Ida, S., Yonekura, T., Kinoshita, Y., Kanamori, Y., et al. (2017) · Clinical Pediatric Endocrinology · doi:10.1297/cpe.26.127 · Cited by 89
Groop, P.-H., Dandona, P., Phillip, M., Gillard, P., Edelman, S., Jendle, J., Xu, J., Scheerer, M. F., Thoren, F., Iqbal, N., et al. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30280-1 · Cited by 79
The interrelationship between sleep, diet, and glucose metabolism
St-Onge, M.-P., Cherta-Murillo, A., Darimont, C., Mantantzis, K., Martin, F. P., & Owen, L. (2023) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2023.101788 · Cited by 79
Weghuber, D., Forslund, A., Ahlström, H., Alderborn, A., Bergström, K., Brunner, S., Cadamuro, J., Ciba, I., Dahlbom, M., Heu, V., et al. (2020) · Pediatric Obesity · doi:10.1111/ijpo.12624 · Cited by 78
Siminerio, L. M., Albanese-O’Neill, A., Chiang, J. L., Hathaway, K., Jackson, C. C., Weissberg-Benchell, J., Wright, J. L., Yatvin, A. L., & Deeb, L. C. (2014) · Diabetes Care · doi:10.2337/dc14-1676 · Cited by 77
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc15-s014 · Cited by 93
Basu (2017) · doi:10.1097/mlr.0000000000000728 · Cited by 77
“Note that a diagnostic code-based algorithm validated against both chart review and laboratory assessment was used, instead of laboratory values alone, because routine guidelines for clinical practice by paramedics and emergency department physicians often call for immediate treatment of suspected hypoglycemia with de…”
MethodThe clinical impact of inpatient hypoglycemia
Brutsaert, E. F., Carey, M., & Zonszein, J. (2014) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2014.03.002 · Cited by 78
“This threshold was recently endorsed by a consensus statement published by the American Diabetes Association and the Endocrine Society working group (Seaquist et al., 2013).”
BackgroundSpeight, J., Barendse, S. M., Singh, H., Little, S. A., Inkster, B., Frier, B. M., Heller, S. R., Rutter, M. K., & Shaw, J. A. M. (2016) · Diabetic Medicine · doi:10.1111/dme.12824 · Cited by 76
Self-citationHypoglycemia, Chronic Kidney Disease, and Diabetes Mellitus
Alsahli, M., & Gerich, J. E. (2014) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2014.07.013 · Cited by 91
Risk Factors and Adverse Outcomes of Severe Hypoglycemia in Type 2 Diabetes Mellitus
Yun, J.-S., & Ko, S.-H. (2016) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2016.40.6.423 · Cited by 75
Thong, E. P., Herath, M., Weber, D. R., Ranasinha, S., Ebeling, P. R., Milat, F., & Teede, H. J. (2018) · Clinical Endocrinology · doi:10.1111/cen.13761 · Cited by 81
Management of diabetes mellitus in older people with comorbidities
Huang, E. S. (2016) · BMJ · doi:10.1136/bmj.i2200 · Cited by 79
on behalf of the CONCLUDE Study Group, Philis-Tsimikas, A., Klonoff, D. C., Khunti, K., Bajaj, H. S., Leiter, L. A., Hansen, M. V., Troelsen, L. N., Ladelund, S., Heller, S., et al. (2020) · Diabetologia · doi:10.1007/s00125-019-05080-9 · Cited by 73
Self-citationSurveillance of hypoglycemia-limitations of emergency department and hospital utilization data
Karter, A. J., Moffet, H. H., Liu, J. Y., & Lipska, K. J. (2018) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2018.1014 · Cited by 73
Heller, S., White, D., Lee, E., Lawton, J., Pollard, D., Waugh, N., Amiel, S., Barnard, K., Beckwith, A., Brennan, A., et al. (2017) · Health Technology Assessment · doi:10.3310/hta21200 · Cited by 73
Self-citationBode, B. W., Johnson, J. A., Hyveled, L., Tamer, S. C., & Demissie, M. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0350 · Cited by 73
HAT Brazil study group, Lamounier, R. N., Geloneze, B., Leite, S. O., Montenegro, R., Zajdenverg, L., Fernandes, M., de Oliveira Griciunas, F., Ermetice, M. N., & Chacra, A. R. (2018) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-018-0379-5 · Cited by 72
Mathieu, C., Rudofsky, G., Phillip, M., Araki, E., Lind, M., Arya, N., Thorén, F., Scheerer, M. F., Iqbal, N., & Dandona, P. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14060 · Cited by 71
“Hypoglycaemic events were defined according to the American Diabetes Association (ADA) classification criteria.(9) Severe hypoglycaemia was defined as an event that resulted in unconsciousness because of”
MethodYeoh, E. C. K., Zainudin, S. B., Loh, W. N., Chua, C. L., Fun, S., Subramaniam, T., Sum, C. F., & Lim, S. C. (2015) · Annals of the Academy of Medicine Singapore · doi:10.47102/annals-acadmedsg.v44n6p202 · Cited by 71
Rickels, M. R. (2019) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14214 · Cited by 71
Effects of glucose-lowering agents on vascular outcomes in type 2 diabetes: A critical reappraisal
Scheen, A. J., & Charbonnel, B. H. (2014) · Diabetes & Metabolism · doi:10.1016/j.diabet.2014.03.004 · Cited by 78
Paramasivam, S. S., Chinna, K., Singh, A. K. K., Ratnasingam, J., Ibrahim, L., Lim, L. L., Tan, A. T. B., Chan, S. P., Tan, P. C., Omar, S. Z., et al. (2018) · Diabetic Medicine · doi:10.1111/dme.13649 · Cited by 69
Sadeghi, O., Keshteli, A. H., Afshar, H., Esmaillzadeh, A., & Adibi, P. (2017) · European Journal of Nutrition · doi:10.1007/s00394-017-1585-x · Cited by 77
“Furthermore, refined grains of high-GI diets results in a postprandial hyperglycemia and hyperinsulinemia [56, 57] and this might decrease blood glucose levels to a concentration which is a threshold for the secretion of autonomic hormones including adrenaline, cortisol, glucagon, and growth hormone [58].”
BackgroundPark, J., Ntelis, S., Yunasan, E., Downton, K. D., Yip, T. C.-F., Munir, K. M., & Haq, N. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad471 · Cited by 69
Reilhac, C., Dubourg, J., Thang, C., Grouin, J., Fouqueray, P., & Watada, H. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14642 · Cited by 86
“Events of hypoglycaemia were categorized according to the American Diabetes Association and the Endocrine Society guidance.(17)”
MethodGomes, M. B., & Negrato, C. A. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2016.07.011 · Cited by 70
Restoration of Glucose Counterregulation by Islet Transplantation in Long-standing Type 1 Diabetes
Rickels, M. R., Fuller, C., Dalton-Bakes, C., Markmann, E., Palanjian, M., Cullison, K., Tiao, J., Kapoor, S., Liu, C., Naji, A., et al. (2015) · Diabetes · doi:10.2337/db14-1620 · Cited by 67
Bonora, E., Frias, J. P., Tinahones, F. J., Van, J., Malik, R. E., Yu, Z., Mody, R., Bethel, A., Kwan, A. Y. M., & Cox, D. A. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14465 · Cited by 67
Metadata
- Authors
- Seaquist, E. R., Anderson, J., Childs, B., Cryer, P., Dagogo-Jack, S., Fish, L., Heller, S. R., Rodriguez, H., Rosenzweig, J., & Vigersky, R.
- Affiliations
- University of Minnesota (US)
- The Frist Clinic, Nashville, Tennessee;
- Mid-America Diabetes Associates, Wichita, Kansas; the
- Washington University in St. Louis (US)
- University of Tennessee Health Science Center (US)
- Park Nicollet Clinic (US)
- University of Sheffield (GB)
- University of South Florida (US)
- Boston University (US)
- Walter Reed National Military Medical Center (US)
- Corresponding author
- Seaquist, Elizabeth R.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2013-04-13
- Volume
- 36
- Issue
- 5
- Pages
- 1384-1395
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3631867
- OpenAlex
- W2109416725
- Cited by
- 1,389
- References
- 141
- Citations by year
- 2026: 43 · 2025: 47 · 2024: 62 · 2023: 66 · 2022: 92 · 2021: 127 · 2020: 119 · 2019: 149 · 2018: 148 · 2017: 151 · 2016: 129 · 2015: 129 · 2014: 92 · 2013: 33
- FWCI
- 100.42
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- American Diabetes Association
- Eli Lilly and Company
- Sanofi
- National Institute for Health and Care Research (NF-SI-0611-10248)
- Novo Nordisk
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Patient Safety and Medication Errors
- Keywords
- hypoglycemia, diabetes mellitus, hypoglycemia definition, hypoglycemia prevention, long-term outcomes, patient counseling, clinical guidelines
- MeSH terms
- Diabetes Mellitus, Humans, Hypoglycemia, Societies, Medical, United States
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-30, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-30 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.